Clinical trials: Neurological Manifestations
Major Depressive Disorder
Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode…
- Trial name
- AtWoRC (NCT02332954)
- Testing
- vortioxetine
- Where
- 26 sites in Canada
- Volunteers
- 226 people
- Sponsor
- Lundbeck Canada Inc.
Sarcopenia, Body Composition
Validation of a Body-Composition Segmentation Software on a Diverse Public CT Scan Cohort
This study evaluates the standalone performance of Soma, a deep-learning software developed by Nucleo Research, Inc. for the automated segmentation of body-composition tissues (skeletal muscle, subcutaneous adipose tissue…
- Conditions
- Sarcopenia, Body Composition, Obesity
- Trial name
- SOMA (NCT07600866)
- Testing
- Soma Body-Composition Segmentation Software
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nucleo Research, Inc.
Back Pain
Pilot Evaluation to Assess the Clinical and Economic Impact of Pfizer's Pain Management Program (painPREMIER) in the Treatment of Low Back Pain, in an Occupational Health Care Setting in Finland
The aim of this investigation is to determine whether the use of painPREMIER will significantly improve function in patients with low back pain in an occupational health clinical setting.
- Trial name
- NCT01787565
- Testing
- painPREMIER cohort, Control cohort
- Where
- Finland
- Volunteers
- 86 people
- Sponsor
- Pfizer
Pain
Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation
The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.
- Trial name
- NCT00412100
- Testing
- Oxycodone naloxone prolonged release tablets (OXN)
- Sponsor
- Mundipharma Research GmbH & Co KG
Hearing Loss, Sensorineural, Hearing Loss, Bilateral
Optimizing Soft Speech Recognition in Children With Hearing Loss
Overhearing is important for vocabulary learning and speech and language development in young children. However, contemporary hearing aids are generally unable to provide adequate access to low-level auditory inputs from multiple…
- Trial name
- SoftSpeech (NCT05299892)
- Testing
- Phonak Audeo P or Naida P hearing aid
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sonova AG
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult participants who have severe-to profound and profound hearing loss due to…
- Trial name
- CHORD (NCT05788536)
- Testing
- DB-OTO
- Where
- 17 sites in United States, Germany and 3 more
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Hearing Loss
Quality Control of CE-Certified Phonak Hearing Aids - 2019_34
Phonak Hearing Devices pass through different development and study phases. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner.
- Trial name
- NCT04187781
- Testing
- external microphone
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Sonova AG
Low Back Pain
A Prospective Study of the InterFuse T(tm),
The purpose of this post-approval study is to demonstrate that the InterFuse T modular lumbar interbody device is at least equal in safety and efficacy to other (standard of care) TLIF devices.
- Trial name
- NCT02678130
- Testing
- InterFuse T, Standard of Care TLIF (Stryker AVS Unilif)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vertebral Technologies, Inc.
Spinal Fractures, Fractures, Compression
The Kiva® System as a Vertebral Augmentation Treatment
The purpose of this study is to evaluate the safety and effectiveness of the Kiva VCF Treatment system in comparison to balloon kyphoplasty for the treatment of osteoporotic vertebral compression fractures of the thoracic or…
- Conditions
- Spinal Fractures, Fractures, Compression, Back Injuries
- Trial name
- KAST (NCT01123512)
- Testing
- Vertebral augmentation
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 300 people
- Sponsor
- Benvenue Medical, Inc.
Seneorineural Deafness, Sudden Sensorineural Hearing Loss
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
The goal of this 2 step-up, exploratory study is to test safey, tolerability and PK/PD profiles in healthy volunteers and safety, tolerability and efficacy in sudden sensorineural hearing loss patients as an early salvage…
- Trial name
- NCT06249919
- Testing
- NS101
- Where
- 15 sites in South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Neuracle Science Co., LTD.
Post Herpetic Neuralgia
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
- Trial name
- NCT01748877
- Testing
- NXN-462
- Where
- 25 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- NeurAxon Inc.
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Nonmalignant and Nonneuropathic Pain
Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.
The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.
- Trial name
- NCT01400139
- Testing
- Hydrocodone bitartrate q24h film-coated tablets
- Where
- 98 sites in United States
- Volunteers
- 922 people
- Sponsor
- Purdue Pharma LP
Chronic Pain
DTM (TM) Spinal Cord Stimulation (SCS) Study
Prospective, multi-center, open-label, post-market study to evaluate the efficacy and energy use of a low energy DTM™ (DTM-LE) SCS therapy for pain relief.
- Trial name
- NCT04601454
- Testing
- Spinal Cord Stimulation System
- Where
- 13 sites in United States
- Volunteers
- 57 people
- Sponsor
- MedtronicNeuro
Postoperative Dental Pain
A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo
Researchers are looking for a better way to relieve pain in people, such as after dental surgery. Participants in this study, have had 3 or 4 third molars (cheek teeth) removed and subsequently have moderate to severe tooth pain.
- Trial name
- NCT05485805
- Testing
- Naproxen sodium and caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine
- Where
- United States
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Bayer
Spasticity
Adult Subjects Suffering From Lower Limb Spasticity Following Stroke
The purpose of the protocol is to assess the responder rate as defined by the achievement of the primary goal from the Goal Attainment Scale following one botulinum toxin type-A (BoNT-A) injection cycle in accordance with routine…
- Trial name
- VALGAS (NCT01444794)
- Where
- 24 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Ipsen
Single Sided Deafness, Tinnitus
Tinnitus Treatment With Cochlear Implant in Single Sided Deafness
Recent studies have reported successful reduction of tinnitus after cochlear implantation (CI) in most CI users, but the mechanisms of reduction and the amount of improvement is not fully understood.
- Conditions
- Single Sided Deafness, Tinnitus, Cochlear Implant
- Trial name
- NCT02966366
- Testing
- Cochlear implant
- Where
- 6 sites in France
- Volunteers
- 27 people
- Sponsor
- Oticon Medical
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
- Trial name
- NCT03268941
- Testing
- TAK-906 Maleate, Metaclopramide
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Pain
A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen
The purpose of this study is to evaluate the impact of extended release tramadol hydrochloride (75 mg) and acetaminophen (650 mg) tablets on improvement of pain.
- Trial name
- NCT01819805
- Testing
- No intervention
- Where
- 14 sites in South Korea
- Volunteers
- 1,065 people
- Sponsor
- Janssen Korea, Ltd., Korea
Dyskinesia, Levodopa Induced Dyskinesia
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 4-arm parallel group study to evaluate the tolerability and efficacy of each of three dose levels of ADS-5102 oral capsules, an extended release formulation of…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
- Trial name
- EASED (NCT01397422)
- Testing
- ADS-5102 (extended release amantadine HCl)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.